Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Craig-Hallum Maintains Buy on Simulations Plus, Raises Price Target to $60

Craig-Hallum Maintains Buy on Simulations Plus, Raises Price Target to $60

Craig-Hallum analyst Matt Hewitt maintains Simulations Plus (NASDAQ:SLP) with a Buy and raises the price target from $55 to $60.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Craig-Hallum analyst Matt Hewitt maintains Simulations Plus (NASDAQ:SLP) with a Buy and raises the price target from $55 to $60.

‘PDS Biotech’s Survival Benefit Is Absurdly Overstated’ – By Adam Feuerstein/ STAT News

By Benzinga Newsdesk

May 16, 11:03 AM

https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it

PDSB

Analyst Ratings

Expert Ratings For AES

By Benzinga Insights

May 17, 2:01 PM

8 analysts have shared their evaluations of AES (NYSE:AES) during the recent three months, expressing a mix of…

AES

BriaCell Images Confirm Robust Anti-Tumor Activity In Patient With “Eye-Bulging” Metastatic Breast Cancer

By Benzinga Newsdesk

January 4, 9:46 AM

Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular painHeavily

BCTX